An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * CABOMETYX® Receives FDA Approval to Treat Neuroendocrine Tumors On March 26, Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Celltrion Receives U.S. FDA Approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) Biosimilars Referencing PROLIA® and XGEVA® On March 3, Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) and OSENVELT® (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves New Treatment Option For A Leading Cause of Diabetes-Related Blindness Genentech, a member of the Roche Group on February 4 announced that the U.S. Food and Drug Administration (FDA) approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Olfactive Biosolutions Granted Third Dual GLP-1 / GIP Patent to Repurpose Food Molecules for Weight Management and Blood Sugar Regulation Olfactive Biosolutions was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in U.S. patent US 12,171,727...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Announces Results from CAH Treatment Trials On December 11, Spruce Biosciences, Inc., announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. Spruce is a late-stage...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amylyx Announces Pivotal Phase 3 GLP-1 Trial Design in Post-Bariatric Hypoglycemia On December 4, Amylyx announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Exelixis, Inc. on November 26 announced that the U.S. Food and Drug Administration (FDA) has notified the company...
